Tianjin's first medical technology transfer organization was established

Recently, Tianjin tipr-huya-aim was founded in Tianjin future science and Technology City, becoming the first professional medical technology transfer organization in the city The center will promote the international connection of pharmaceutical innovation achievements in Tianjin and even the whole country, and promote the development process of new pharmaceutical technologies in China Taipu Shanghai Asia intellectual property transfer and reserve center is jointly funded by Tianjin Pharmaceutical Research Institute, a leader in new drug research and development in China, and Shanghai Asia biology in the United States The institution will promote the transfer of patented technology in this city to foreign countries, and will also assist more foreign high-end technology to transfer to China, and enable more patented technology to achieve application and create wealth through patent licensing, transaction, pledge financing, equity and other forms The center will use the R & D strength, human resources of the pharmaceutical research institute and Shanghai Asia's experience in the global technology transfer of new drugs to screen and evaluate excellent new drug achievements, accelerate the transfer of new drug technology, and jointly carry out new drug development At present, the company has established extensive cooperative relationship with Chinese pharmaceutical academic and commercial institutions, according to the person in charge of the company Shanghai Asia Research Institute has more than 14000 compound combination databases in treatment fields, which can maximize the innovative value of China's biomedicine In addition, in the future, Shanghai Asia company will also strive to introduce the most advanced foreign medical products and technologies to China at the lowest price, so as to reduce the pain and burden for patients.